论文部分内容阅读
目的:了解1986—2002年瑞典药品补偿政策改革引起的药品费用与数量的变化趋势。方法:利用瑞典所有已经注册的药品和5个指标药来评价1986—2002年补偿政策改革的结果,并由瑞典国家药品公司提供全国所有药房的药品交易数据。这期间有五次补偿政策改革,其中有三次提高共付比例,一次启用参考价格机制和提高累积个人支付费用和一次补偿政策的结构调整。结果:分阶段线性回归分析,增加累计个人支付费用,药品的费用和数量变化没有相关关系;新的补偿政策导致总药品和某些指标药的费用和数量的水平下降;启用参考定价政策减少了总药品和5个指标药的限定日剂量的价格水平。结论:补偿制度的大调整对药品的费用,数量和价格有明显影响,即新的补偿政策(新的结构调整)使药品费用和数量有所减少,启用参考定价政策会导致药品单价降低。
OBJECTIVE: To understand the changing trend of drug costs and quantities caused by the reform of drug compensation policy in Sweden from 1986 to 2002. METHODS: The results of the compensation reform for 1986-2002 were evaluated using all registered Swedish medicines and five indicator drugs, and the Swedish national drug company provided drug transaction data for all pharmacies in the country. During this period, there were five compensation policy reforms, of which three were made to raise the co-pay ratio, one was to activate the reference price mechanism and the structural adjustment of the cumulative individual payment fee and the one-time compensation policy was implemented. Results: Staged linear regression analysis showed that there was no correlation between the increase of accumulated individual payment and the change of the cost and quantity of medicines. The new compensation policy led to the decrease of the cost and quantity of total medicines and some indicator medicines. The introduction of the reference pricing policy reduced The total drug and the five index drugs limit the daily dose price level. CONCLUSIONS: The major adjustment of the compensation system has a significant effect on the cost, quantity and price of medicines. That is, the new compensation policy (new structural adjustment) reduces the cost and quantity of medicines, and the introduction of a reference pricing policy will result in a decrease in the unit price of medicines.